WASHINGTON — The Food and Drug Administration can’t escape questions about Aduhelm.
Patrizia Cavazzoni, one of the agency’s highest-ranking drug regulators, set out to testify before Congress Thursday on the intricacies of three looming funding bills crucial to the agency’s operations. But again and again, lawmakers grilled her about Biogen’s controversial Alzhiemer’s drug.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
